Interleukin-6, C-reactive protein and interleukin-10 after antidepressant treatment in people with depression: A meta-analysis

Psychological Medicine

Volumn 42, Issue 10, 2012, Pages 2015-2026

  Hiles, S A ^a   Baker, A L ^a   De Malmanche, T ^b   Attia, J ^c,d  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b JOHN HUNTER HOSPITAL   (Australia)

^c UNIVERSITY OF NEWCASTLE   (Australia)

^d JOHN HUNTER HOSPITAL   (Australia)

Author keywords

C reactive protein; depression; inflammation; interleukin; meta analysis; systematic review

Indexed keywords

ANTIDEPRESSANT AGENT; C REACTIVE PROTEIN; INTERLEUKIN 10; INTERLEUKIN 6;

ARTICLE; BLOOD; CROSS-SECTIONAL STUDY; DEPRESSION; HUMAN; INFLAMMATION; META ANALYSIS;

ANTIDEPRESSIVE AGENTS; C-REACTIVE PROTEIN; CROSS-SECTIONAL STUDIES; DEPRESSIVE DISORDER; HUMANS; INFLAMMATION; INTERLEUKIN-10; INTERLEUKIN-6;

EID: 84871512229     PISSN: 00332917     EISSN: 14698978     Source Type: Journal    
DOI: 10.1017/S0033291712000128     Document Type: Review

References (51)

1. Basterzi AD, Aydemir C, Kisa C, Aksaray S, Tuzer V, Yazici K, Goka E (2005). IL-6 levels decrease with SSRI treatment in patients with major depression. Human Psychopharmacology 20, 473-476.
2. Bland JM, Altman DG (1994). Statistics notes : Some examples of regression towards the mean. British Medical Journal 309, 780.
3. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR (2009). Introduction to Meta-analysis. John Wiley & Sons: Chichester, UK.
4. Bossola M, Ciciarelli C, Di Stasio E, Conte GL, Vulpio C, Luciani G, Tazza L (2010). Correlates of symptoms of depression and anxiety in chronic hemodialysis patients. General Hospital Psychiatry 32, 125-131.
5. Carvalho LA, Garner BA, Dew T, Fazakerley H, Pariante CM (2010). Antidepressants, but not antipsychotics, modulate GR function in human whole blood : An insight into molecular mechanisms. European Neuropsychopharmacology 20, 379-387.
6. Carvalho LA, Pariante CM (2008). In vitro modulation of the glucocorticoid receptor by antidepressants. Stress : The International Journal on the Biology of Stress 11, 411-424.
7. Chen Y-C, Lin W-W, Chen Y-J, Mao W-C, Hung Y-J (2010). Antidepressant effects on insulin sensitivity and proinflammatory cytokines in the depressed males. Mediators of Inflammation. Published online : 18 May 2010. doi:10.1155/2010/573594.
8. Dawood T, Lambert EA, Barton DA, Laude D, Elghozi JL, Esler MD, Haikerwal D, Kaye DM, Hotchkin EJ, Lambert GW (2007). Specific serotonin reuptake inhibition in major depressive disorder adversely affects novel markers of cardiac risk. Hypertension Research 30, 285-293.
9. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, Lanctôt KL (2010). A meta-analysis of cytokines in major depression. Biological Psychiatry 67, 446-457.
10. Egger M, Davey Smith G, Schneider M, Minder C (1997). Bias in meta-analysis detected by a simple, graphical test. British Medical Journal 315, 629-634.
11. Evans DL, Charney DS, Lewis L, Golden RN, Gorman JM, Krishnan KRR, Nemeroff CB, Bremner JD, Carney RM, Coyne JC, Delong MR, Frasure-Smith N, Glassman AH, Gold PW, Grant I, Gwyther L, Ironson G, Johnson RL, Kanner AM, Katon WJ, Kaufmann PG, Keefe FJ, Ketter T, Laughren TP, Leserman J, Lyketsos CG, McDonald WM, McEwen BS, Miller AH, Musselman D, O'Connor C, Petitto JM, Pollock BG, Robinson RG, Roose SP, Rowland J, Sheline Y, Sheps DS, Simon G, Spiegel D, Stunkard A, Sunderland T, Tibbits JP, Valvo WJ (2005). Mood disorders in the medically ill : Scientific review and recommendations. Biological Psychiatry 58, 175-189.
12. Fornaro M, Martino M, Battaglia F, Colicchio S, Perugi G (2011). Increase in IL-6 levels among major depressive disorder patients after a 6-week treatment with duloxetine 60 mg/day: A preliminary observation. Neuropsychiatric Disease and Treatment 7, 51-56.
13. Gabay C, Kushner I (1999). Acute-phase proteins and other systemic responses to inflammation. New England Journal of Medicine 340, 448-454.
14. Hernandez ME, Mendieta D, Martinez-Fong D, Loria F, Moreno J, Estrada I, Bojalil R, Pavon L (2008). Variations in circulating cytokine levels during 52 week course of treatment with SSRI for major depressive disorder. European Neuropsychopharmacology 18, 917-924.
15. Higgins JPT, Thompson SG, Deeks JJ, Altman DG (2003). Measuring inconsistency in meta-analyses. British Medical Journal 327, 557-560.
16. Howren MB, Lamkin DM, Suls J (2009). Associations of depression with C-reactive protein, IL-1, and IL-6 : A metaanalysis. Psychosomatic Medicine 71, 171-186.
17. Irwin MR, Miller AH (2007). Depressive disorders and immunity: 20 years of progress and discovery. Brain, Behavior, and Immunity 21 374-383.
18. Janssen DGA, Caniato RN, Verster JC, Baune BT (2010). A psychoneuroimmunological review on cytokines involved in antidepressant treatment response. Human Psychopharmacology 25, 201-215.
19. Jazayeri S, Keshavarz SA, Tehrani-Doost M, Djalali M, Hosseini M, Amini H, Chamari M, Djazayery A (2010). Effects of eicosapentaenoic acid and fluoxetine on plasma cortisol, serum interleukin-1beta and interleukin-6 concentrations in patients with major depressive disorder. Psychiatry Research 178, 112-115.
20. Kagaya A, Kugaya A, Takebayashi M, Fukue-Saeki M, Saeki T, Yamawaki S, Uchitomi Y (2001). Plasma concentrations of interleukin-1beta, interleukin-6, soluble interleukin-2 receptor and tumor necrosis factor alpha of depressed patients in Japan. Neuropsychobiology 43, 59-62.
21. Kenis G, Maes M (2002). Effects of antidepressants on the production of cytokines. International Journal of Neuropsychopharmacology 5, 401-142.
22. Khan AMD, Brodhead AEMS, Schwartz KAMS, Kolts RLP, Brown WAMD (2005). Sex differences in antidepressant response in recent antidepressant clinical trials. Journal of Clinical Psychopharmacology 25, 318-324.
23. Kubera M, Kenis G, Bosmans E, Zieba A, Dudek D, Nowak G, Maes M (2000). Plasma levels of interleukin-6, interleukin-10, and interleukin-1 receptor antagonist in depression : Comparison between the acute state and after remission. Polish Journal of Pharmacology 52, 237-241.
24. Lanquillon S, Krieg JC, Bening-Abu-Shach U, Vedder H (2000). Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology 22, 370-379.
25. Leo R, Di Lorenzo G, Tesauro M, Razzini C, Forleo GB, Chiricolo G, Cola C, Zanasi M, Troisi A, Siracusano A, Lauro R, Romeo F (2006). Association between enhanced soluble CD40 ligand and proinflammatory and prothrombotic states in major depressive disorder : Pilot observations on the effects of selective serotonin reuptake inhibitor therapy. Journal of Clinical Psychiatry 67, 1760-1766.
26. Lindqvist D, Janelidze S, Hagell P, Erhardt S, Samuelsson M, Minthon L, Hansson O, Bjorkqvist M, Traskman-Bendz L, Brundin L (2009). Interleukin-6 is elevated in the cerebrospinal fluid of suicide attempters and related to symptom severity. Biological Psychiatry 66, 287-292.
27. Mackay GM, Forrest CM, Christofides J, Bridel MA, Mitchell S, Cowlard R, Stone TW, Darlington LG (2009). Kynurenine metabolites and inflammation markers in depressed patients treated with fluoxetine or counselling. Clinical and Experimental Pharmacology and Physiology 36, 425-435.
28. Maes M (2001). The immunoregulatory effects of antidepressants. Human Psychopharmacology : Clinical and Experimental 16, 95-103.
29. Maes M, Bosmans E, De Jongh R, Kenis G, Vandoolaeghe E, Neels H (1997). Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine 9, 853-858.
30. Maes M, Meltzer HY, Bosmans E, Bergmans R, Vandoolaeghe E, Ranjan R, Desnyder R (1995). Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. Journal of Affective Disorders 34, 301-309.
31. Maes M, Yirmyia R, Noraberg J, Brene S, Hibbeln J, Perini G, Kubera M, Bob P, Lerer B, Maj M (2009). The inflammatory and neurodegenerative hypothesis of depression : Leads for future research and new drug developments in depression. Metabolic Brain Disease 24, 27-53.
32. Mikova O, Yakimova R, Bosmans E, Kenis G, Maes M (2001). Increased serum tumor necrosis factor alpha concentrations in major depression and multiple sclerosis. European Neuropsychopharmacology 11, 203-208.
33. Miller AH, Maletic V, Raison CL (2009). Inflammation and its discontents : The role of cytokines in the pathophysiology of major depression. Biological Psychiatry 65, 732-741.
34. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A (2001). Interleukin-10 and the interleukin-10 receptor. Annual Review of Immunology 19, 683-765.
35. O'Brien SM, Scott LV, Dinan TG (2006). Antidepressant therapy and C-reactive protein levels. British Journal of Psychiatry 188, 449-452.
36. O'Donovan A, Hughes BM, Slavich GM, Lynch L, Cronin M-T, O'Farrelly C, Malone KM (2010). Clinical anxiety, cortisol and interleukin-6 : Evidence for specificity in emotion-biology relationships. Brain, Behavior, and Immunity 24, 1074-1077.
37. Park HS, Park JY, Yu R (2005). Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-a and IL-6. Diabetes Research and Clinical Practice 69, 29-35.
38. Pizzi C, Mancini S, Angeloni L, Fontana F, Manzoli L, Costa GM (2009). Effects of selective serotonin reuptake inhibitor therapy on endothelial function and inflammatory markers in patients with coronary heart disease. Clinical Pharmacology & Therapeutics 86, 527-32.
39. Pudar Hozo S, Djulbegovic B, Hozo I (2005). Estimating the mean and variance from the median, range, and the size of a sample. BMC Medical Research Methodology 5(13).
40. Rosenthal R (1979). The file drawer problem and tolerance for null results. Psychological Bulletin 86, 638-641.
41. Rothermundt M, Arolt V, Fenker J, Gutbrodt H, Peters M, Kirchner H (2001). Different immune patterns in melancholic and non-melancholic major depression. European Archives of Psychiatry and Clinical Neuroscience 251, 90-97.
42. Rush AJ, Zimmerman M, Wisniewski SR, Fava M, Hollon SD, Warden D, Biggs MM, Shores-Wilson K, Shelton RC, Luther JF, Thomas B, Trivedi MH (2005). Comorbid psychiatric disorders in depressed outpatients : Demographic and clinical features. Journal of Affective Disorders 87, 43-55.
43. Serretti A, Mandelli L (2010). Antidepressants and body weight: A comprehensive review and meta-analysis. Journal of Clinical Psychiatry 71, 1259-1272.
44. Sluzewska A, Rybakowski JK, Laciak M, Mackiewicz A, Sobieska M, Wiktorowicz K (1995). Interleukin-6 serum levels in depressed patients before and after treatment with fluoxetine. Annals of the New York Academy of Sciences 762, 474-476.
45. Sluzewska A, Sobieska M, Rybakowski JK (1997). Changes in acute-phase proteins during lithium potentiation of antidepressants in refractory depression. Neuropsychobiology 35, 123-127.
46. Song C, Halbreich U, Han C, Leonard BE, Luo H (2009). Imbalance between pro-and anti-inflammatory cytokines, and between Th1 and Th2 cytokines in depressed patients : The effect of electroacupuncture or fluoxetine treatment. Pharmacopsychiatry 42, 182-188.
47. Tuglu C, Kara SH, Caliyurt O, Vardar E, Abay E (2003). Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder. Psychopharmacology 170, 429-433.
48. Tummers B, van der Laan J, Huyser K (2008). Data Thief III, v. 1.5, computer software (http://datathief.org/). Accessed 8 September 2010.
49. Yao H, Tao L-G, Zhang X-B, Sha W-W, Hou G, Zhang Z-J (2004). Variety of cell-mediated immunity and the metabolic products of monoamine neural transmitter in depression patients before and after therapy. Chinese Journal of Clinical Rehabilitation 8, 2978-2979.
50. Yoshimura R, Hori H, Ikenouchi-Sugita A, Umene-Nakano W, Ueda N, Nakamura J (2009). Higher plasma interleukin-6 (IL-6) level is associated with SSRI-or SNRI-refractory depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry 33, 722-726.
51. Zorrilla EP, Luborsky L, McKay JR, Rosenthal R, Houldin A, Tax A, McCorkle R, Seligman DA, Schmidt K (2001). The relationship of depression and stressors to immunological assays : A meta-analytic review. Brain, Behavior and Immunity 15, 199-226.